Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease

Launched by MCMASTER UNIVERSITY · Aug 7, 2024

Keywords

ClinConnect Summary

This clinical trial is looking into why some patients with Inflammatory Bowel Disease (IBD), like Crohn's disease and ulcerative colitis, continue to experience persistent abdominal pain even when their disease is not actively flaring up. Researchers believe this ongoing pain might be linked to certain bacteria in the gut that produce substances called LPC and LPA, which can make the gut more sensitive. The goal is to understand the relationship between these bacteria and the pain symptoms, as well as identify which specific bacteria are responsible for this issue.

To participate in this study, individuals must be between 18 and 70 years old and have a diagnosis of either Crohn's disease or ulcerative colitis, along with a history of moderate or severe abdominal pain that continues even when their condition is stable. However, people currently taking certain medications, like strong pain relievers or antibiotics, or those with other specific health issues, may not be eligible. Participants can expect to provide samples and information about their symptoms over time, helping researchers gain insights that could improve the treatment of chronic pain in IBD patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 and 70 years of age
• • Crohn's disease diagnosis with history of past or current moderate or severe chronic abdominal pain that persist despite colitis being in remission (absence of overt inflammation on CT or MRI imaging, and baseline fecal calprotectin of less than 200 μg/g of stool), or in presence of mild inflammation defined by colonoscopy (Simple Endoscopic Score for Crohn's Disease score: 0-10),
• • Ulcerative colitis diagnosis with history of past or current moderate or severe chronic abdominal pain that persist despite colitis being in remission (absence of overt inflammation on CT or MRI imaging, and baseline fecal calprotectin less than 200 μg/g of stool) or in presence of mild inflammation defined by colonoscopy (Endoscopic Mayo score: 0-1)
• Exclusion Criteria:
• • Current acid anti-secretory and antacid medications
• • Antibiotics, antibacterial agents or probiotics, currently, or within the last 8 weeks
• • Current pain treatment with opioids or NSAIDs (acetaminophen is permitted)
• • Alcohol or drug abuse
• • Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be a risk or that could interfere with data collection